Registry for young-onset diabetes and its genetic factors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a comprehensive registry for young-onset diabetic patients, focusing on Maturity-Onset Diabetes of the Young (MODY) and its various subtypes. It will collect detailed clinical data, including health history, medication use, and family history, along with biological samples for genetic testing. The study will analyze the distribution of MODY types, their clinical characteristics, and responses to antidiabetic medications. By understanding the genetic underpinnings and clinical manifestations, the research seeks to improve precision medicine approaches for young-onset diabetes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Case Group Diagnosis of diabetes at or before 25 years of age. BMI (Body Mass Index) of 25 kg/m² or lower. Having at least one parent diagnosed with type 2 diabetes.
2. Family Group Direct blood relatives of the case group, including brothers and sisters of the case group, who have contacted the research team through the subjects.

   Expressing willingness to participate in this study after granting informed consent.
3. Control Group Diagnosis of diabetes occurred at or before the age of 40, and the individual lacks typical MODY (Maturity-Onset Diabetes of the Young) characteristics.

At least one parent has been diagnosed with type 2 diabetes.

Exclusion Criteria:

1. Confirmed Diagnosed with type 1 diabetes.
2. Under 18 years of age.
3. Unable to personally provide informed consent.
4. Patients with unrelieved leukemia.
5. Patients who have undergone chemotherapy or radiation therapy for cancer within the last 12 months.
6. Cases that have received a blood transfusion within the last six months.
7. Unwilling or unable to continue treatment follow-up at this hospital.

Where it's running

• Taichung veterans general hospital
  Taichung, Taiwan Recruiting

Study contacts

• Principal investigator: Yi-Jing Sheen, MD. PHD — Division of Endocrinology and Metabolism in Taichung Veterans General Hospital
• Study coordinator: Yi-Jing Sheen, MD. PHD
• Email: docmedjean@gmail.com
• Phone: 886-4-2359-2525

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Acute Blood Flow Restriction Walking in Type 2 Diabetes

  This study tests whether adding blood flow restriction to treadmill walking affects immune cells in adults with type 2 diabetes.

  Recruiting University of British Columbia · Kelowna, British Columbia · NCT07928531

• Continuous Glucose Monitoring in Type 2 Diabetes Not on Insulin

  This study tests whether using a continuous glucose monitoring system helps people with type 2 diabetes who aren’t using insulin to improve blood sugar control and quality of life.

  Recruiting Medical University of Bialystok · Bialystok · NCT07919236

• Differentiating heart disease in autoimmune vs. type 2 diabetes

  This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.

  Recruiting University of Roma La Sapienza · Rome, Roma · NCT07911007

• Lifestyle Metabotype Study B: Understanding Personalized Glucose Responses

  This study tests how lifestyle, metabolism, and brain energy use relate to each person’s blood sugar response after meals, across people with and without prediabetes or type 2 diabetes.

  Recruiting at 2 sites German Institute of Human Nutrition · Berlin and 1 other locations · NCT07888257

• Lifestyle Metabotype Study: How Daily Habits Shape Blood Sugar

  This observational study tests whether personal lifestyle and biological factors can predict how a person’s blood sugar responds after meals.

  Recruiting German Institute of Human Nutrition · Potsdam, Potsdam-Rehbrücke · NCT07868601

• Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes

  This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07868354

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.